ArrayExpress Uploader03160not responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapynot responsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyresponsive to imatinib therapyarrayexpress_sid4Newly diagnosed chronic phase chronic myeloid leukemia (CML) patients with a major cytogenetic response (MCyR) after 12 months of...19837975E-GEOD-14671/profile/8773/arrayexpressuploader159chronic myeloid leukemialeukemiamyeloid leukemiaDec.12, 2014Falsetranscription-profiling-of-cd34-positive-mononucleE-GEOD-14671_A-AFFY-44Transcription profiling of CD34 positive mononuclear cells from drug naive, chronic myeloid leukemia (CML) patients to determine an expression signature predictive of a major cytogenic response in CML patients treated with Imatinib.Sep.11, 2014Newly diagnosed chronic phase chronic myeloid leukemia (CML) patients with a major cytogenetic response (MCyR) after 12 months of imatinib therapy have an excellent long-term outcome, while patients without MCyR have a high progression risk. Since patients with primary cytogenetic resistance may benefit from more intensive therapy up-front, we sought to identify biomarkers to predict MCyR. Keywords: Two group comparison to identify trasncriptomic signature that predicts response to therapy CD34+ cells were isolated from cryopreserved mononuclear cells of chronic phase CML patients with a complete cytogenetic response (CCyR) or >65% Ph-positive metaphases after 12 months of imatinib therapy (training set N=36). Gene expression profiles generated on amplified RNA using Affymetrix HG-U133 Plus 2.0 arrays were compared between responders and non-responders, using the criteria ANOVA p<0.1 and fold difference >I1.5I. A minimal response classifier derived from the comparison was used to predict response in a prospectively collected validation set using same criteria for responders/nonresponders (N=23).http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-14671humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-14671/samples/